OncoSec Medical, Inc. is a biotechnology company pioneering
new technologies designed to stimulate the body’s immune system to target and
attack cancer. The company is currently conducting preclinical and clinical
studies targeting various cancers using its proprietary investigational
platform, ImmunoPulse™. Early study results have laid the groundwork for
OncoSec’s eventual expansion into new DNA-encoded therapeutic candidates and
tumor indications, which will allow the company to continue on its mission to
harness the body’s immune system and take the fight against cancer directly to
the tumor.
Based in San Diego, OncoSec currently has a promising
clinical pipeline with four ongoing studies utilizing both monotherapy with the
company’s ImmunoPulse™ IL-12 immunotherapy platform and specialized combination
therapy. The company is currently proceeding with trials studying the safety
and efficacy of its platform in treating multiple stages of metastatic
melanoma, head and neck cancer, and triple negative breast cancer. These studies
could prove to be monumental in the global battle against various forms of
cancers, as illustrated by statistical data surrounding melanoma.
Despite accounting for less than two percent of skin cancer
cases, melanoma causes a large majority of skin cancer deaths, according to the
American Cancer Society. With diagnosis rates steadily increasing for more than
three decades, the demand for improved treatment options is at an all-time
high. In 2015, it’s estimated that over 73,000 new melanoma cases will be diagnosed
and nearly 10,000 people are expected to die from the disease.
ImmunoPulse™ focuses on the delivery of DNA-based
interleukin-12 (IL-12), which is a naturally occurring protein that’s been
shown as effective in delivering immune-stimulating functions, directly to the
tumor through a sequence of short electrical pulses. By establishing a
localized presence of this powerful protein in the tumor microenvironment, the
patient’s immune system learns to target and attack tumors throughout the body.
Early data from OncoSec’s trials is promising. The company’s
multi-center Phase II trial recorded an overall response in nearly one-third of
patients, with half of all patients showing complete regression in at least one
untreated lesion. By reliably promoting regression in an untreated area, the
company has a powerful proof of concept of the effectiveness of its immune
system boosting platform.
Promising results have led to several significant
collaborations throughout the biopharmaceutical industry for OncoSec. To date,
the company is working with Merck, Heat Biologics, PerkinElmer and Plexxikon on
clinical and preclinical collaborations to further study the effectiveness of
its ImmunoPulse™ platform.
“With the support of our shareholders, we look forward to
validating our ImmunoPulse™ technology in clinical and preclinical studies,
generating more value for our investors, and securing our place in this
long-awaited revolution in cancer treatment,” stated Punit Dhillon, Chief
Executive Officer and President of OncoSec.
For more information, visit www.oncosec.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment